Information Density: Gavi, the Vaccine Alliance – Signal Evidence & AI Readability

[H2] Leaving no one behind with immunisation
Gavi, the Vaccine Alliance is a public-private partnership that helps vaccinate more than half the world’s children against some of the world's deadliest diseases.About us Explore our Progress Report

29 May 2026

Why are women more likely to get autoimmune diseases like lupus and multiple sclerosis?
A million-cell study points to baseline sex-related genetic differences in the immune system.
Research summary

[IMG: Photo by Fotos on Unsplash]

Read more

29 May 2026

DRC Ebola outbreak exposes community health gaps
As the DRC battles a rapidly growing Ebola outbreak, investment in community health surveillance is critical, writes Githinji Gitahi.
Cross-postsEbolaOutbreaks

[IMG: A police post in Guinea with]

Read more

28 May 2026

Scientists found 54 viruses in indoor dust: could this help us track disease outbreaks?
Researchers in the US have shown that ordinary indoor dust can reveal which viruses have been circulating in a building, opening up a possible new front in disease surveillance.
OutbreaksResearch summary

[IMG: A dusty attic. Photo by Mika Baumeister on Unsplash]

Read more

VaccinesWork is an award-winning digital platform hosted by Gavi, covering news, features and explainers from every corner of global health and immunisation.

[H2] The Gavi Leap

[H2] The Gavi Leap
The Gavi Leap is the most ambitious reform agenda in global health, offering a blueprint for broader reform of the health and development architecture. Learn more about how Leap principles, such as country ownership, radical simplification and innovation, are already having a tangible impact on how immunisation is delivered in Gavi-supported countries.
Latest on the Leap

[IMG: The Gavi Leap]

[H2] Our work

[IMG: A mother with her child in Tanzania. Credit: Doune Porter]
[H3] Vaccine portfolio
Gavi supports vaccines against 20 infectious diseases, including Ebola, malaria, mpox and rabies.View our vaccines

[IMG: A health worker in Tanzania. Credit: Gavi/2012/P Rudden]
[H3] Health systems support
Strong health and immunisation systems are vital to deliver vaccines to all the children who need them.Learn more

[IMG: A health worker carrying vaccines in a cold box in Somalia. Credit: Gavi]
[H3] Civil society support
We provide grants for civil society organisations (CSOs) working to reach zero-dose children and missed communities with vaccines.Our work with CSOs

[IMG: Gavi/2024/Mohamed Abdihakim Ali]
[H3] Shaping vaccine markets
Working to improve the health of markets for vaccines and other immunisation products.Learn more

29 May 2026

Gavi commits US$ 50 million to Bundibugyo Ebolavirus vaccines and outbreak response

[IMG: Health workers conduct interviews as part of Ebola eradication efforts in the ​Democratic ​Republic ​of ​the Congo during the 2018-2020 Ebola outbreak. Credit: Gavi/2019/Frederique Tissandier.]

Read news

22 May 2026

Gavi statement on scaling innovative financing for the next pandemic
As part of its Gavi Leap reforms, Gavi remains committed to working with countries and partners to accelerate and strengthen coordination on pandemic financing.

Read news

21 May 2026

Gavi statement on the Ebola disease outbreak in Democratic Republic of the Congo and Uganda
Gavi, the Vaccine Alliance is closely monitoring the Ebola disease outbreak caused by Bundibugyo virus that is currently affecting the Democratic Republic of the Congo (DRC) and Uganda.

Read news

[H2] The Vaccine Alliance

[H2] The Vaccine Alliance
Gavi draws on the skills of a variety of partners, combining the technical expertise of the development community with the business know-how of the private sector.
Meet our partners

[IMG: The Vaccine Alliance]

[H2] Gavi 6.0 funding guidelines
Newly released funding guidelines outline the scope of Gavi’s vaccine and cash support for the 2026–2030 strategic period (Gavi 6.0), explain how countries should plan and prioritise their immunisation programmes within this support, clarify the requirements for the Gavi 6.0 country application and describe how to access other forms of assistance such as outbreak and emergency support.Access the guidelines

[IMG: World Map]

[H2] Partner countries

[H2] Partner countries
Since its inception in 2000, Gavi has helped to immunise a whole generation – over 1.2 billion children – and prevented more than 20.6 million future deaths, helping to halve child mortality in 78 lower‑income countries.
Explore partner countries

[H2] Our donors

[H2] Our donors
As a public-private partnership, Gavi is funded by governments, foundations, institutions, organisations, corporations and private individuals.
Meet our donors

[IMG: Global Summit 2025]

[H2] Our impact
Download our facts & figures

[H2]

>1.2
billion
children vaccinated through routine programmes

>20.6
million
future deaths averted

17
countries
fully self-financing

>280
US$ billion
in economic benefits for countries

2.1
billion
vaccinations through preventive vaccination campaigns

[H3] GAVI, THE VACCINE ALLIANCE SECRETARIAT
Geneva, SwitzerlandTel: +41 22 909 6500Fax: +41 22 909 6550info@gavi.orgMedia enquiries: media@gavi.org
[H4] Mailing and visiting address:
Global Health CampusChemin du Pommier 401218 Le Grand-SaconnexSwitzerland
[H3] DIRECTIONS
View Larger Map

[H3] GAVI, THE VACCINE ALLIANCE SECRETARIAT
Washington DCTel: +1 202 478 1050Fax: +1 202 478 1060DCOfficeServices@gavi.org

Last updated: 10 Apr 2026

Gavi, the Vaccine Alliance is a public-private partnership that helps vaccinate more than half the world’s children against some of the world’s deadliest diseases.The Vaccine Alliance brings together partner country and donor governments, the World Health Organization (WHO), UNICEF, the World Bank, the vaccine industry, technical agencies, civil society, the Gates Foundation and other private sector partners.Since its inception in 2000, Gavi has helped to immunise a whole generation – over 1.2 billion children –and prevented more than 20.6 million future deaths, helping to halve child mortality in 78 lower-income countries.Gavi also plays a key role in improving global health security by supporting health systems as well as funding global stockpiles for Ebola, cholera, meningococcal and yellow fever vaccines.See progress report       See facts and figures

The Vaccine Alliance employs innovative finance and the latest technology – from drones to biometrics – to save lives, prevent outbreaks before they can spread and help countries on the road to self-sufficiency.Gavi’s 2026–2030 strategic period is the most ambitious in its history – providing access to the widest, most innovative portfolio of critical life-saving vaccines ever. The Alliance will support countries to vaccinate more than 500 million more children and adolescents. At the same time, our reform programme, the Gavi Leap, is truly placing countries first by increasing country decision-making over financial resources.

[IMG: Vaccine Alliance partners]

[H2] The power of partnership

[H2] The power of partnership
Gavi’s impact draws on the strengths of its founding partners – the World Health Organization (WHO), UNICEF, the World Bank and the Gates Foundation – and plays a critical role in strengthening primary health care (PHC), bringing us closer to the Sustainable Development Goal (SDG) of Universal Health Coverage (UHC), ensuring that no one is left behind.Gavi also works with donors, including sovereign governments, private sector foundations and corporate partners; NGOs, advocacy groups, professional and community associations, faith-based organisations and academia; vaccine manufacturers, including those in low- and middle-income countries; research and technical health institutes; and implementing country governments.
Our partners

Our primary mission is life critical. Our goal is very clear: to address the gross inequities in child health still existing in the world today. Life or death for a young child too often depends on whether he is born in a country where vaccines are available or not.

Nelson Mandela
Founding Chair of the Vaccine Fund Board (Gavi’s initial financing arm)

[H2] Gavi’s impact
More children survive. The increase in immunisation has helped to halve child mortality by averting more than 20.6 million future deaths, and dramatically driven down the incidence of deadly and debilitating infectious diseases.Economies thrive. As children become healthier, they, their families, communities and countries are more able to be economically prosperous and socially stable. For every US$ 1 spent on immunisation in Gavi-supported countries in the 2021–2030 period, US$ 21 are saved in health care costs, lost wages and lost productivity due to illness and death. When considering the value people place on lives saved by vaccines – which is likely to include the value of costs averted plus the broader societal value of lives saved and people living longer and healthier lives – the return on investment is estimated to be US$ 54 per US$ 1 spent. In Gavi’s first 25 years, our work helped generate more than US$ 280 billion in economic benefits in the countries we support.And global health security improves. In the face of global challenges, such as climate change, population growth, urbanisation, human migration, fragility and conflict, Gavi has helped countries broaden vaccine coverage and improve their health systems. This makes them less susceptible and better able to prevent disease outbreaks that pose a threat to people in these countries, protecting millions of others around the world.

Download our facts & figuresLearn about Gavi’s history

[H2] A proven model
Every year, Gavi-supported vaccines reach more than half of the world’s children, giving it tremendous power to negotiate vaccines at prices that are affordable for the lowest-income countries and to remove the commercial risks that previously kept manufacturers from serving them. Through Gavi’s market shaping efforts, the number of manufacturers supplying prequalified Gavi-supported vaccines has grown, from 5 in 2001 to 20 in 2024 (with nearly half based in low- and middle-income countries).Gavi shares the cost that implementing countries pay for vaccines, which has resulted in more than 695 vaccine introductions and preventive vaccination campaigns, dramatically boosting immunisation against virulent diseases. For example, in 2000, 3% of low-income countries had introduced nationally Haemophilus influenzae type b (Hib) vaccine that protects against diseases like pneumonia and meningitis.

Gavi has enabled all low-income countries to introduce this vaccine in their national programmes. Today, Gavi-supported countries continue to have higher coverage of vaccines against Hib, pneumococcus and rotavirus than the rest of the world. As of 2022, 19 countries had transitioned out of Gavi support and are fully self-financing vaccine programmes introduced with Gavi support.Learn more about our work
[IMG: Parents with their child in Bangladesh. Credit: Gavi/2023/Ashraful Arefin]
Parents with their child in Bangladesh. Credit: Gavi/2023/Ashraful Arefin

Last updated: 7 May 2026

Skip to main content